Next Phase Newsletter

A life sciences venture capital with offices in Central Hong Kong currently manages a fund with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $10-20M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm can invest both public and private companies in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the USA and China. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics companies. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in AI-driven medical devices. The firm is willing to invest companies at any stage of development.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Shenzhen, China was founded in the 1990s and currently has about 1.5 billion RMB in assets under management. The firm is currently investing out of their $30 million USD fund. The firm focuses on Series A-B deals within the USA, Canada, and China and typically invests $2-5 million USD per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, the firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact investment fund based in San Francisco, California is investing from a $400 million fund, and makes investments in several sectors including cleantech, IT and healthcare. As the firm invests in a variety of sectors and stages, allocations vary considerably but initial investments are typically between $5-15 million. The firm primarily invests in the USA but also has the ability to invest worldwide. The firm typically leads investment rounds but is also open to co-investing as part of a strong syndicate. The firm plans to invest in a total of 25-30 companies from the current fund.

In healthcare, the firm is interested in healthcare IT, medical device and diagnostic startups that have an approved product or a product that does not require FDA approval. The firm also wants to see evidence that the company’s approach has efficacy in achieving a health benefit or impact. While the firm will consider any indication area, the firm has a preference for investing in chronic diseases, including diabetes and prediabetes, and also behavioral conditions.

The firm does not invest in companies that still face regulatory risks for their products. The firm also places a strong emphasis on reimbursement and/or the product having established a revenue generating model.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A California-based investment firm manages several innovative venture capital funds. The funds invest in early, growth, and expansion-stage technology and life science companies. The firm closed its second fund in July 2015 and principally invests in early and growth-stage investments in Series A, B, and C preferred equity rounds with other top-tier institutional and corporate investors. The firm will lead investments with their third fund. The investment size is variable and dependent on the company’s capitalization plan and future capital requirements. The firm currently focuses its’ investment activities in parts of the western USA that are under-served by venture capital such as Southern California, the southwest, and northwest. The firm is actively seeking institutional investment limited partners and new investment opportunities.

In the Life Sciences area, the firm seeks to invest in medical device, product, diagnostics, specialty pharma, and healthcare IT. The firm is opportunistic in terms of sub-sectors and indications. The firm generally seeks clinical stage therapeutics that are at least Phase II, and diagnostics and medical devices that are very close to or with FDA approval.

The funds are led by a seasoned VC with a track record of investing. The firm generally co-invests with other top-tier institutional and corporate investors, and will work with companies to help them organize an investment syndicate. The firm seeks investment opportunities in rapidly growing companies with world-class products and solutions that address major market needs; along with talented leadership, management teams, and boards with deep industry experience and track records of success.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects that have significant entry barrier and can address unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity investment firm based in Israel seeks early stage companies to form and establish, as well as investing to bridge the gap between late stage companies in Israel and companies with sales activity in the U.S. and Europe (“platforms”). The firm currently has a $130M fund that the firm is both allocating out of and raising with an aim of $300M. For early-stage companies, the firm typically invests from a few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. The firm may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in diabetes, obesity, heart failure, structural heart, pulmonary hypertension, currently looking at neurology and urology, and is open to new areas of focus. For late-stage/Platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new $125M life sciences venture fund affiliated with a leading research university is focused on early-stage healthcare technology in seed, Series A/B rounds. The firm is opportunistic geographically, though has preference for companies based in the USA.

The firm is interested in therapeutics, medical devices, and healthcare IT. The firm is opportunistic with particular interest in neuroscience, oncology, osteopathy, and ophthalmology products. In healthcare IT, the firm is interested in AI and augmented reality in life sciences. The firm seeks preclinical to clinical stage products.

The firm does not have a specific management team requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.